Sinus Surgeries and Interventions (for Tennessee Only)
Customize your policy alerts
Sign up for UnitedHealthcare Policy CS138TN.Q alerts
Get alerted when Policy CS138TN.Q changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coverage criteria for balloon sinus ostial dilation and functional endoscopic sinus surgery (FESS) for Tennessee Medicaid and CoverKids members, and describes related devices and evidence considerations.
Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records documentation may be required to assess whether the member meets clinical criteria for coverage.
Added definition of 'Acute Bacterial Rhinosinusitis'.
Removed definitions for the Draf Classification System for Endoscopic Frontal Sinus Drainage and Rhinitis Medicamentosa (RM).
Updated descriptions of services, clinical evidence, and references to reflect the most current information; archived previous policy version CS138TN.P.
Coverage Criteria for Sinus Procedures
Chronic Rhinosinusitis (CRS) - Coverage Criteria
Covered when ALL of the following are met
CT documentation must include which sinus and extent (percent opacification or use of Modified Lund-Mackay) and CT findings such as bony remodeling, bony thickening, opacified sinus, or ostial obstruction with mucosal thickening.
Balloon Sinus Ostial Dilation Specific Limitations
Covered when ALL of the following are met
Balloon dilation is not supported for sinonasal polyps or tumors.
FESS Additional Indications
FESS is also covered when any of the following CT-confirmed conditions are present
For maxillary, frontal, or sphenoid sinuses, both ostial obstruction and mucosal thickening must be present (ethmoid requires mucosal thickening).
Recurrent Acute Rhinosinusitis (RARS) - Coverage Criteria
Covered when ALL of the following are met
Consideration of surgical intervention when episodes are frequent and medical management or productivity loss justifies intervention.
Guideline-based coverage criteria
Guideline and trial-based coverage considerations
Support from AAO-HNS, ARS, NICE position statements and guideline summaries.
AAO-HNS consensus statements caution against use without objective disease.
Per AAO-HNS and ARS position statements and practice guidance.
Philpott et al. randomized trial (514 participants).
ESS — medical necessity and guideline-based criteria
Covered when documentation meets guideline-supported indications and criteria:
ESS candidacy (general)
- Cardinal symptoms: At least two of: nasal drainage, nasal obstruction, facial pain/pressure, decreased sense of smell
AAO-HNS diagnostic criteria
- Objective evidence: Findings on anterior rhinoscopy, nasal endoscopy, or CT showing edema, abnormal mucus, polyps, or sinus inflammation
AAO-HNS documentation of inflammation
- Medical therapy failure: Documented trial of tailored medical therapy (intranasal corticosteroids and saline irrigations; systemic therapy as clinically indicated) with inadequate response
AAO-HNS and allergy society recommendations
AAO-HNS and allergy society indications
ACR and AAO-HNS recommendations
EUFOREA position paper recommendations for offering ESS in uncomplicated CRSsNP
ESS and surgical intervention candidacy
Covered when ALL of the following are met (per cited guideline recommendations and policy supporting evidence):
ACR and EUFOREA specify CT as imaging method of choice and recommend CT prior to surgery.
ICAR-RS and EUFOREA cited.
EUFOREA and ICAR-RS criteria referenced.
ICAR-RS and AAO-HNS cite endoscopy or CT findings as criteria.
Balloon sinus ostial dilation is explicitly not supported for treatment of sinonasal polyps or tumors due to insufficient evidence of efficacy. The policy also states that self-expanding absorptive sinus ostial dilation devices remain investigational and are considered unproven and not medically necessary for evaluation or treatment of sinusitis and other indications because available studies are limited and do not provide comparative effectiveness data.
Balloon dilation should not be performed in patients who lack sinonasal symptoms or who have sinonasal symptoms but a CT that does not show evidence of sinonasal disease. Clinical guidance summarized in the policy states that balloon dilation is not appropriate for management of isolated headache or sleep apnea when the patient does not otherwise meet criteria for CRS or RARS.
The policy discourages basing the decision for surgery solely on arbitrary imaging findings such as mucosal thickening or sinus opacification without clinical correlation. Imaging should be interpreted in the context of symptoms, quality-of-life burden, and objective findings (endoscopy or CT) when determining candidacy for balloon dilation or FESS.
Self-expanding absorptive sinus ostial dilation devices have limited clinical evidence. Existing studies are small, often lack comparison groups, and provide insufficient data to establish effectiveness or safety compared with standard care; therefore, the policy does not support these devices for routine clinical use.
Balloon sinus ostial dilation and FESS are considered not medically necessary when the clinical and imaging criteria specified in the policy are not met. Likewise, self-expanding absorptive dilation is designated unproven and not medically necessary for treating sinusitis because the evidence does not demonstrate clear benefit.
Randomized data do not support balloon dilation for barometric pressure–related sinus headache when CT imaging shows no mucosal disease. A blinded RCT found no significant difference between active sinus ostial balloon dilation and a placebo nasal dilation procedure in SNOT-22 or HIT-6 outcomes at follow-up, indicating no demonstrated benefit for that indication.
Routine use of prolonged low-dose clarithromycin for CRS is not supported by randomized trial evidence cited in the policy. A randomized trial comparing ESS to prolonged clarithromycin showed superior symptom improvement after surgery, and guideline summaries referenced in the policy do not recommend prolonged low-dose macrolide therapy as a routine alternative to surgical management when surgery is otherwise indicated.
The policy does not provide an explicit list of procedures that are categorically not medically necessary within this excerpt, but it emphasizes that FDA clearance or approval alone is not a basis for coverage. Devices cleared by the FDA (for example the SinuSys Vent-OS) remain subject to assessment of clinical evidence before coverage is supported.
Coding and Key Clinical Thresholds
| 31240 | Nasal/sinus endoscopy, surgical; with concha bullosa resection. |
| 31253 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed. |
| 31254 | Nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior). |
| 31255 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior). |
| 31256 | Nasal/sinus endoscopy, surgical, with maxillary antrostomy. |
| 31257 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy. |
| 31259 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy, with removal of tissue from the sphenoid sinus. |
| 31267 | Nasal/sinus endoscopy, surgical, with maxillary antrostomy; with removal of tissue from maxillary sinus. |
| 31276 | Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed. |
| 31287 | Nasal/sinus endoscopy, surgical, with sphenoidotomy;. |
| LRC | FDA product code: instrument, ENT, manual surgical |
Provider Requirements, Authorization, and Documentation
Tennessee Medicaid/CoverKids prior authorization required
This policy applies to Tennessee Medicaid and CoverKids; clinical coverage requires documentation that the member meets the policy’s clinical criteria for sinus surgery procedures (see Coverage Criteria). Applicable CPT codes are listed in the policy and should be included with authorization requests.
- Include procedure code(s) relevant to planned sinus surgery (see Applicable CPT Codes).
- Attach clinical documentation demonstrating criteria in Coverage Rationale.
Document failed medical therapy and objective findings
Prior authorization requests must document failure of appropriate medical therapy and include objective confirmation of disease (nasal endoscopy or CT) because guidelines require objective findings before balloon sinus ostial dilation.
- Document specific failed therapies and dates.
- Include nasal endoscopy findings or CT images/reports showing mucosal thickening or ostial occlusion.
Document prior medical management and failure
Prior medical therapy and evidence of inadequate response must be documented before surgery; documentation should state tailored medical management including intranasal corticosteroids and saline irrigations, and antibiotics when bacterial infection is suspected.
- Record type, dose, duration, and response to intranasal corticosteroids.
- Document use of saline irrigation and any antibiotic courses, with indication and outcome.
Coverage decisions may require medical record review
Benefit coverage is determined by federal, state, or contractual requirements; medical records may be requested to determine whether the member meets clinical criteria for coverage and such documentation does not by itself guarantee coverage.
- Be prepared to provide complete medical records, including history, exam, and diagnostic test results, upon request.
- Understand that plan-specific terms may supersede this policy when they differ.
Verify prior authorization and plan terms
This policy is guidance for standard benefit plans; verify plan-specific prior authorization requirements and federal/state/contractual terms for the member’s coverage before proceeding.
- Check member’s federal, state, or contractual plan documents for any differing coverage terms.
- Confirm whether a plan-level prior authorization is required and follow that process.
Conservative medical management required and must be documented
Conservative medical management is required prior to surgical coverage for CRS and should be documented; typical measures include intranasal corticosteroids, antibiotics if bacterial infection is suspected, and nasal irrigation.
- Document intranasal corticosteroid use (agent, dose, duration).
- Record antibiotic use only when purulent discharge or bacterial infection suspected, with dates and response.
- Document nasal lavage/irrigation use.
Attempt and document conservative therapy before surgery
Medical management (intranasal corticosteroids, saline irrigations, and antibiotics when indicated) is the recommended first-line therapy and should be attempted and recorded prior to considering ESS.
- Document trials of intranasal corticosteroids and saline irrigations.
- If antibiotics used, note indication (e.g., purulence) and treatment response.
Stepwise medical management must be documented before ESS
Attempt and document stepwise medical therapy before ESS: topical intranasal steroids and saline irrigation are mainstays; antibiotics should be used only when purulent discharge or bacterial infection is suspected.
- Record duration and response to topical intranasal steroids and saline irrigation.
- Document rationale and results for any antibiotic therapy.
Document trial of maximal medical therapy and symptom scoring
For uncomplicated adult CRSsNP, document a trial of maximal medical therapy — typically at least 8 weeks of topical intranasal corticosteroid plus a short systemic antibiotic or prolonged low‑dose anti-inflammatory antibiotic — and record symptom scores (e.g., SNOT‑22) as applicable.
- Document duration (≥8 weeks) and specifics of topical intranasal corticosteroid therapy.
- Include posttreatment SNOT-22 score if available (EUFOREA recommends ≥20 for offering ESS).
Maintain comprehensive medical record documentation
The patient’s medical record must document relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures to support medical necessity; records must be legible, maintained, and made available upon request.
- Include history of symptom duration and prior treatments.
- Attach physical exam findings and diagnostic test results (endoscopy, CT) supporting indication.
Obtain and include preprocedure CT showing objective disease
Obtain CT imaging of the sinuses (fine‑cut, non‑contrast maxillofacial CT) before balloon dilation; include objective CT evidence such as mucosal thickening, ostial obstruction, or other findings correlating with symptoms.
- CT should be obtained after completion of medical management when feasible.
- Include documentation of which sinus is affected and extent of disease (percent opacification or Lund‑Mackay scoring).
Document CRS diagnostic criteria and objective evidence
Include clinical documentation that meets CRS diagnostic criteria: symptoms for ≥12 weeks with at least two cardinal symptoms and objective evidence of inflammation on endoscopy or CT to support medical necessity for surgery.
- Document symptom types and duration (≥12 weeks) and at least two cardinal symptoms.
- Attach endoscopy findings or CT reports demonstrating inflammation, polyps, edema, or purulence.
Ensure records fully support medical necessity and are available on request
Ensure the patient medical record fully supports medical necessity for the requested service, including relevant history, physical exam, and diagnostic test results; records must be available for review and legible.
- Provide chronological documentation of prior therapies and responses.
- Ensure imaging and endoscopy reports are included and clearly linked to symptoms.
Check federal, state, and contractual plan documents first
Before using this policy, check the member’s federal, state, or contractual plan documents because those terms govern in the event of a conflict and may alter coverage or prior authorization requirements.
- Confirm whether contractual plan terms require different authorization steps or coverage determinations.
- If plan terms conflict with this policy, follow the governing contractual or state/federal requirements.
Denial risk: insufficient documentation
Lack of medical record documentation supporting medical necessity — including history, exam, and diagnostic test results — may lead to claim denial or inability to determine coverage.
- Avoid omissions: include symptom duration, prior treatments, exam findings, and imaging/endoscopy reports.
- Be prepared to submit records when requested to prevent denial.
Denial risk for inappropriate indications (no CT/symptoms)
Performing balloon dilation without CT evidence of sinonasal disease, or in patients without sinonasal symptoms and positive CT findings, is considered inappropriate and may result in noncoverage or denial.
- Do not submit authorization for balloon dilation when CT lacks evidence of disease.
- Include both symptom documentation and corresponding CT/endoscopy findings to justify the procedure.
Denial risk: missing diagnostic criteria or failed therapy documentation
Absence of documented diagnostic criteria (symptom duration ≥12 weeks with ≥2 cardinal symptoms) or objective inflammation (endoscopy or CT), or lack of documented failed medical therapy, may prevent justification of ESS and risk denial.
- Document at least two cardinal symptoms and duration ≥12 weeks.
- Attach objective findings (endoscopy or CT) and records of prior medical therapy and response.
Denial risk if records are not provided on request
Failure to provide requested medical records that support medical necessity may lead to denial or inability to determine coverage; be prepared to furnish complete records when requested by the plan.
- Respond promptly to record requests and include all relevant documentation.
- Ensure records are legible and maintained in the patient’s chart.
Follow federal/state/contractual plan terms when conflicts exist
Coverage decisions must follow federal, state, or contractual benefit requirements; if this policy conflicts with those terms, the governing contractual or legal requirements control and may affect coverage determination.
- When in doubt, prioritize the member’s contractual or state/federal coverage provisions over this policy.
- Verify any plan-specific mandates prior to submitting authorization requests.
Background and Evidence Summary
Rhinosinusitis is inflammation of the paranasal sinuses and nasal cavities and is classified by duration and etiology. Acute rhinosinusitis lasts less than 4 weeks, whereas chronic rhinosinusitis (CRS) is defined as symptoms persisting for 12 weeks or longer with at least two cardinal symptoms (nasal drainage, nasal obstruction, facial pain/pressure, or diminished sense of smell) and objective documentation of inflammation by endoscopy or imaging.
Definitions and Clinical Terms
Policy Revision History
Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records documentation may be required to assess whether the member meets clinical criteria for coverage; specified required content of medical record documentation.
Added definition of 'Acute Bacterial Rhinosinusitis' and updated several related definitions (Acute Rhinosinusitis, Chronic Rhinosinusitis, Functional Endoscopic Sinus Surgery, Modified Lund-Mackay Scoring System, Recurrent Acute Rhinosinusitis).
Updated descriptions of services, clinical evidence, and references; archived previous policy version CS138TN.P.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.